Supernus Pharmaceuticals Inc (SUPN) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Summary

Supernus Pharmaceuticals Inc (Supernus) is a specialty pharmaceutical company which develops and commercializes products for the treatment of central nervous system (CNS) diseases. The companys neurology portfolio consists of Oxtellar XR (oxcarbazepine), an adjunct therapy for the treatment of partial seizures; and Trokendi XR (topiramate), an initial monotherapy against partial onset or primary generalized tonic-clonic seizures and an adjunct therapy for the treatment of primary generalized tonic-clonic seizures associated with Lennox-Gastaut syndrome. Its technology platforms include Microtrol (multiparticulate delivery platform), Solutrol (matrix delivery platform) and EnSoTrol (osmotic delivery system). The company operates through its subsidiary Supernus Europe Ltd. Supernus is headquartered in Rockville, Maryland, the US.

Supernus Pharmaceuticals Inc (SUPN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.


List of Tables 4
List of Figures 4
Supernus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Supernus Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Supernus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Supernus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Supernus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Supernus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 10
Private Equity 10
HealthCare Royalty Acquires Orenitram from Supernus Pharma for USD30 Million 10
Licensing Agreements 11
Supernus Pharma Enters into Licensing Agreement with Zydus Pharma 11
Aequus Pharma Enters into Licensing Agreement with Supernus Pharma 12
Especificos Stendhal Enters into Licenisng Agreement with Supernus Pharma 13
Equity Offering 14
Supernus Pharma Completes Public Offering Of Common Stock For US$48 Million 14
Supernus Pharma Completes IPO For USD52.3 Million 16
Debt Offering 18
Supernus Pharma Prices Private Placement of Notes Due 2023 for USD350 Million 18
Supernus Pharma Completes Private Placement Of Notes Due 2019 For US$90 Million 19
Supernus Pharmaceuticals Inc - Key Competitors 21
Supernus Pharmaceuticals Inc - Key Employees 22
Supernus Pharmaceuticals Inc - Locations And Subsidiaries 23
Head Office 23
Other Locations & Subsidiaries 23
Recent Developments 24
Financial Announcements 24
May 08, 2018: Supernus Reports First Quarter 2018 Financial Results 24
Feb 27, 2018: Supernus Announces Record Full Year 2017 Financial Results, Exceeding Operating Earnings Guidance 26
Nov 06, 2017: Supernus Announces Third Quarter 2017 Financial Results 28
Aug 02, 2017: Supernus Announces Record Second Quarter 2017 Financial Results 30
May 09, 2017: Supernus Announces First Quarter 2017 Financial Results 32
Feb 28, 2017: Supernus Announces Record Fourth Quarter and Full Year 2016 Financial Results 34
Corporate Communications 36
Jun 27, 2018: Supernus Pharmaceuticals Names Dr. Carrolee Barlow As Board Director 36
Appendix 37
Methodology 37
About GlobalData 37
Contact Us 37
Disclaimer 37

List Of Tables

List of Tables
Supernus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Supernus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Supernus Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Supernus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Supernus Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Supernus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
HealthCare Royalty Acquires Orenitram from Supernus Pharma for USD30 Million 10
Supernus Pharma Enters into Licensing Agreement with Zydus Pharma 11
Aequus Pharma Enters into Licensing Agreement with Supernus Pharma 12
Especificos Stendhal Enters into Licenisng Agreement with Supernus Pharma 13
Supernus Pharma Completes Public Offering Of Common Stock For US$48 Million 14
Supernus Pharma Completes IPO For USD52.3 Million 16
Supernus Pharma Prices Private Placement of Notes Due 2023 for USD350 Million 18
Supernus Pharma Completes Private Placement Of Notes Due 2019 For US$90 Million 19
Supernus Pharmaceuticals Inc, Key Competitors 21
Supernus Pharmaceuticals Inc, Key Employees 22
Supernus Pharmaceuticals Inc, Subsidiaries 23

List Of Figures

List of Figures
Supernus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Supernus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Supernus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Supernus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Supernus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Supernus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Supernus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Supernus Pharmaceuticals Inc (SUPN) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Supernus Pharmaceuticals Inc (Supernus) is a specialty pharmaceutical company which develops and commercializes products for the treatment of central nervous system (CNS) diseases. The companys neurology portfolio consists of Oxtellar

USD 250 View Report

Supernus Pharmaceuticals Inc Company Profile - Business Operations, Strategies, SWOT Analysis and Financial Report

Supernus Pharmaceuticals Inc Company Profile is a detailed strategic and analytical report on Supernus Pharmaceuticals Inc. The 2018 version of the report offers detailed insights into the companys strategies, developments,

USD 200 View Report

Constellation Pharmaceuticals Inc (CNST) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Constellation Pharmaceuticals Inc (Constellation) is a clinical biopharmaceutical company that focuses to develop novel therapeutics for the treatment of serious unmet medical needs in patients with cancers associated with abnormal

USD 250 View Report

Cannabics Pharmaceuticals Inc (CNBX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Cannabics Pharmaceuticals Inc (Cannabics Pharmaceuticals), formerly Thrust Energy Corp, is a drug development company that develops cannabinoid-based therapies for cancer. The company develops High Content Screening (HCS) Platform, an automated

USD 250 View Report

Your are not allow to send sample request

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available